
Novo Nordisk Launches $9B Bid to Outpace Pfizer in Obesity Drug Market
Novo Nordisk has made a $6 billion cash bid to acquire Metsera, escalating a bidding war with Pfizer, which had previously offered $4.9 billion. The move comes amid Novo's recent struggles, including a significant stock decline and leadership changes, and faces political and legal scrutiny due to concerns over market dominance and antitrust laws. The outcome of this bid could impact the competitive landscape of the weight-loss pharmaceutical market.
